News | November 10, 2025
Novo Nordisk India partners with Emcure to commercialise Poviztra in India
Poviztra is a second brand of Wegovy
Poviztra is a second brand of Wegovy
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Encouraging early detection and breaking the silence around men’s health
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
Triggering global regulatory submissions this year for the treatment of obesity
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Subscribe To Our Newsletter & Stay Updated
